<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Collagen and <z:e sem="disease" ids="C0042974" disease_type="Disease or Syndrome" abbrv="">von Willebrand</z:e> factor (VWF) are considered essential to initiate platelet deposition at sites of vascular injury, but their respective roles remain to be elucidated </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We used a model of carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> induced by a <z:chebi fb="2" ids="30808">ferric chloride</z:chebi> injury to compare the time to first occlusion and occlusion rate at 25 min postinjury in mice lacking the collagen receptor, <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (GP) VI, or the ligand-binding domain of the VWF receptor, GP Ibalpha </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: In <z:mpath ids='MPATH_458'>normal</z:mpath> mice used as controls (n = 12), a <z:e sem="disease" ids="C0001168" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">complete obstruction</z:e> of blood flow developed within 8.05 +/- 0.47 min (mean +/- <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>), and the occlusion rate was 100% </plain></SENT>
<SENT sid="3" pm="."><plain>The results were variable in 26 GP VI(-/-) mice </plain></SENT>
<SENT sid="4" pm="."><plain>The artery never occluded in eight mice, but the time to first occlusion in the remaining 18 (8.36 +/- 0.27 min) was not different from <z:mpath ids='MPATH_458'>normal</z:mpath> (P = 0.556) </plain></SENT>
<SENT sid="5" pm="."><plain>Nonetheless, the occlusion rate was 42%, because in seven mice the occluded artery reopened and stayed patent at 25 min </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, the artery never occluded in 12 mice lacking GP Ibalpha </plain></SENT>
<SENT sid="7" pm="."><plain>In ex vivo perfusion experiments, GP VI(-/-) platelets failed to form <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> onto collagen type I fibrils, but formed <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> of <z:mpath ids='MPATH_458'>normal</z:mpath> size when exposed to endothelial or fibroblast extracellular matrix </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Absence of GP Ibalpha function has a more profound antithrombotic effect in vivo than absence of the GP VI-dependent pathway of collagen-induced <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>/activation </plain></SENT>
<SENT sid="9" pm="."><plain>Components of the extracellular matrix may elicit a thrombogenic response in the absence of GP VI but not GP Ibalpha </plain></SENT>
</text></document>